Bupropion side effects: what 98,116 FDA adverse event reports show
Drug class
Aminoketone antidepressant
Who reports
98,116 reports · 51% serious · 4,722 with death outcome · 73% female
Used for
1. INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets, USP (XL) is an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.
What it is
Bupropion is an aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) • Monitor for worsening and emergence of suicidal thoughts and behaviors.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1,149 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Temperature regulation disorder | 499 | 63.2 57.2–69.8ROR 63.5 · χ² 23,418 / p <1e-300 | 48.7 EB05 45.2 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=492 · ♀ 100% (drug 73%) | not reported in cached trials |
| Stool analysis abnormal | 67 | 45.9 35.3–59.8ROR 46.0 · χ² 2,380 / p <1e-300 | 37.5 EB05 30.6 · IC025 +4.5 3/3 methods agree | Reporting / coding artifact | ♀ 0% (drug 73%) · 100% consumer | not reported in cached trials |
| Ejection fraction | 103 | 45.6 36.9–56.4ROR 45.6 · χ² 3,654 / p <1e-300 | 37.4 EB05 31.7 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=103 · ♀ 100% (drug 73%) | not reported in cached trials |
| Sensitisation | 121 | 40.0 32.9–48.6ROR 40.0 · χ² 3,831 / p <1e-300 | 33.6 EB05 28.9 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=120 · ♀ 100% (drug 73%) | not reported in cached trials |
| Retinitis | 181 | 25.9 22.2–30.2ROR 25.9 · χ² 3,834 / p <1e-300 | 23.1 EB05 20.4 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=181 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Polycystic ovaries | 139 | 20.7 17.4–24.6ROR 20.7 · χ² 2,349 / p <1e-300 | 18.9 EB05 16.4 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=136 · ♀ 100% (drug 73%) | not reported in cached trials |
| Food allergy | 621 | 19.1 17.6–20.7ROR 19.2 · χ² 9,732 / p <1e-300 | 17.6 EB05 16.4 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=598 · ♀ 100% (drug 73%) | not reported in cached trials |
| Postictal state | 82 | 18.3 14.6–23.0ROR 18.3 · χ² 1,219 / p 2e-267 | 16.9 EB05 14.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=81 | not reported in cached trials |
| Joint destruction | 121 | 17.8 14.8–21.5ROR 17.9 · χ² 1,758 / p <1e-300 | 16.5 EB05 14.1 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=121 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Rheumatoid factor positive | 415 | 16.5 14.9–18.2ROR 16.6 · χ² 5,587 / p <1e-300 | 15.4 EB05 14.1 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious n=414 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Lupus vulgaris | 83 | 15.9 12.8–19.9ROR 16.0 · χ² 1,067 / p 2e-234 | 14.8 EB05 12.3 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=83 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Obstructive sleep apnoea syndrome | 92 | 15.0 12.2–18.5ROR 15.0 · χ² 1,110 / p 1e-243 | 14.0 EB05 11.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=88 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Oesophageal spasm | 118 | 14.6 12.1–17.5ROR 14.6 · χ² 1,381 / p <1e-300 | 13.6 EB05 11.6 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=114 · ♀ 100% (drug 73%) | NCT01601704: 1/4,450 (0.0%) control (serious AE) |
| Bone erosion | 217 | 13.9 12.1–15.9ROR 13.9 · χ² 2,422 / p <1e-300 | 13.0 EB05 11.6 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=216 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Libido increased | 113 | 12.5 10.4–15.2ROR 12.6 · χ² 1,122 / p 3e-246 | 11.8 EB05 10.0 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=57 | NCT01601704: 2/4,455 (0.0%) on Bupropion |
| Foetal death | 288 | 12.5 11.1–14.1ROR 12.5 · χ² 2,869 / p <1e-300 | 11.8 EB05 10.7 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=288 · ♀ 100% (drug 73%) | not reported in cached trials |
| Red blood cell sedimentation rate abnormal | 128 | 12.4 10.4–14.8ROR 12.4 · χ² 1,254 / p 5e-275 | 11.6 EB05 10.0 · IC025 +3.2 3/3 methods agree | Lab value / disease marker | serious n=126 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Pre-existing condition improved | 341 | 12.2 10.9–13.6ROR 12.2 · χ² 3,290 / p <1e-300 | 11.5 EB05 10.5 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=188 | not reported in cached trials |
| Coeliac disease | 530 | 12.1 11.1–13.3ROR 12.2 · χ² 5,115 / p <1e-300 | 11.5 EB05 10.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 15.5 · ♀ 100% (drug 73%) | NCT01601704: 2/4,450 (0.0%) control |
| Immunodeficiency | 772 | 11.8 10.9–12.7ROR 11.9 · χ² 7,198 / p <1e-300 | 11.2 EB05 10.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 13.7 · ♀ 100% (drug 73%) | not reported in cached trials |
| Electrocardiogram qrs complex prolonged | 264 | 11.6 10.2–13.1ROR 11.6 · χ² 2,408 / p <1e-300 | 11.0 EB05 9.9 · IC025 +3.2 3/3 methods agree | Lab value / disease marker | serious n=264 · 100% clinician | not reported in cached trials |
| Hostility | 131 | 11.4 9.6–13.6ROR 11.4 · χ² 1,173 / p 2e-257 | 10.8 EB05 9.3 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious n=102 | not reported in cached trials |
| Gambling disorder | 134 | 11.0 9.3–13.1ROR 11.1 · χ² 1,153 / p 4e-253 | 10.4 EB05 9.0 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=107 | not reported in cached trials |
| Grand mal convulsion | 458 | 10.9 10.0–12.0ROR 11.0 · χ² 3,923 / p <1e-300 | 10.4 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 11.9 | not reported in cached trials |
| Hallucinations, mixed | 203 | 10.8 9.4–12.4ROR 10.8 · χ² 1,704 / p <1e-300 | 10.2 EB05 9.1 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | serious n=196 | not reported in cached trials |
| Bursitis | 570 | 10.5 9.7–11.5ROR 10.6 · χ² 4,685 / p <1e-300 | 10.1 EB05 9.4 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 13.0 · ♀ 94% (drug 73%) | NCT01601704: 1/4,455 (0.0%) on Bupropion (serious AE) |
| Tongue biting | 95 | 10.2 8.3–12.6ROR 10.2 · χ² 745 / p 2e-164 | 9.6 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=86 | not reported in cached trials |
| Medication residue | 118 | 10.0 8.4–12.1ROR 10.1 · χ² 909 / p 5e-200 | 9.5 EB05 8.1 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | 76% consumer | not reported in cached trials |
| Product odour abnormal | 456 | 9.8 8.9–10.7ROR 9.8 · χ² 3,425 / p <1e-300 | 9.3 EB05 8.6 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
| Psychiatric decompensation | 85 | 9.7 7.8–12.0ROR 9.7 · χ² 625 / p 3e-138 | 9.1 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=84 · ♀ 0% (drug 73%) · 100% clinician | not reported in cached trials |
| Drug tolerance | 215 | 9.4 8.2–10.8ROR 9.4 · χ² 1,538 / p <1e-300 | 8.9 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=190 | not reported in cached trials |
| Diabetic neuropathy | 208 | 9.3 8.1–10.7ROR 9.3 · χ² 1,463 / p <1e-300 | 8.8 EB05 7.9 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=202 | not reported in cached trials |
| Rhinitis allergic | 185 | 9.2 8.0–10.7ROR 9.3 · χ² 1,295 / p 6e-284 | 8.8 EB05 7.8 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=176 | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 294 | 9.2 8.2–10.3ROR 9.2 · χ² 2,046 / p <1e-300 | 8.8 EB05 7.9 · IC025 +2.9 3/3 methods agree | Lab value / disease marker | serious PRR 10.0 · ♀ 100% (drug 73%) · 100% clinician | not reported in cached trials |
| Sleep apnoea syndrome | 791 | 9.2 8.5–9.9ROR 9.2 · χ² 5,520 / p <1e-300 | 8.8 EB05 8.3 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious PRR 11.2 | not reported in cached trials |
| Therapeutic response unexpected with drug substitution | 168 | 8.8 7.6–10.3ROR 8.8 · χ² 1,113 / p 3e-244 | 8.4 EB05 7.4 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | serious n=97 | not reported in cached trials |
| Depressive symptom | 140 | 8.8 7.5–10.5ROR 8.8 · χ² 925 / p 2e-203 | 8.4 EB05 7.2 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious n=96 · ♀ 43% (drug 73%) | not reported in cached trials |
| Drug screen false positive | 109 | 8.6 7.1–10.4ROR 8.6 · χ² 699 / p 3e-154 | 8.1 EB05 6.9 · IC025 +2.7 3/3 methods agree | Lab value / disease marker | 100% consumer | not reported in cached trials |
| Compulsive shopping | 80 | 8.6 6.8–10.7ROR 8.6 · χ² 505 / p 3e-112 | 8.0 EB05 6.6 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=60 · 100% consumer | not reported in cached trials |
| Major depression | 276 | 8.3 7.4–9.4ROR 8.3 · χ² 1,705 / p <1e-300 | 8.0 EB05 7.2 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious PRR 8.9 | NCT01601704: 3/4,455 (0.1%) on Bupropion (serious AE) |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Bupropion as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (5 of 40 signal terms matched).
- NCT06090461 — Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.) (N=31889, phase n/a; 3 AE terms posted; arms: Contrave/Mysimba; Lorcaserin; Naltrexone and Bupropion (N&B))
- NCT01601704 — Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascul (N=8910, PHASE3; 634 AE terms posted; arms: NB32; Placebo)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 9,484 | 1.5 1.5–1.6ROR 1.6 · χ² 1,919 / p <1e-300 | 1.5 EB05 1.5 · IC025 +0.6 | Reporting / coding artifact | serious PRR 1.9 | not reported in cached trials |
| Nausea | 7,751 | 2.1 2.1–2.2ROR 2.2 · χ² 4,656 / p <1e-300 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.4 | NCT01601704: 1/4,455 (0.0%) on Bupropion (serious AE) |
| Fatigue (tiredness) | 7,121 | 2.0 1.9–2.0ROR 2.0 · χ² 3,485 / p <1e-300 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled (related wording) related wording | serious PRR 2.5 | NCT01601704: 13/4,455 (0.3%) on Bupropion; 1/4,450 (0.0%) control |
| Headache | 6,977 | 2.4 2.3–2.5ROR 2.5 · χ² 5,786 / p <1e-300 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.1 | NCT01601704: 1/4,450 (0.0%) control (serious AE) |
| Depression | 6,322 | 6.1 5.9–6.2ROR 6.4 · χ² 26,198 / p <1e-300 | 5.9 EB05 5.8 · IC025 +2.5 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 6.3 | NCT01601704: 1/4,450 (0.0%) control (serious AE) |
| Anxiety | 5,646 | 4.3 4.2–4.4ROR 4.5 · χ² 14,173 / p <1e-300 | 4.2 EB05 4.1 · IC025 +2.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.5 | NCT01601704: 26/4,455 (0.6%) on Bupropion; 8/4,450 (0.2%) control |
| Pain | 5,281 | 1.8 1.8–1.9ROR 1.9 · χ² 2,072 / p <1e-300 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | serious PRR 2.4 | NCT01601704: 2/4,455 (0.0%) on Bupropion; 3/4,450 (0.1%) control (serious AE) |
| Dizziness | 5,053 | 2.2 2.1–2.2ROR 2.2 · χ² 3,274 / p <1e-300 | 2.2 EB05 2.1 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.5 | NCT01601704: 4/4,455 (0.1%) on Bupropion; 1/4,450 (0.0%) control (serious AE) |
| Off label use (used outside approved label) | 4,537 | 1.1 1.1–1.1ROR 1.1 · χ² 58 / p 1e-14 | 1.1 EB05 1.1 · IC025 +0.1 | Reporting / coding artifact | serious PRR 1.5 | not reported in cached trials |
| Insomnia (trouble sleeping) | 4,513 | 3.7 3.6–3.8ROR 3.8 · χ² 8,684 / p <1e-300 | 3.6 EB05 3.5 · IC025 +1.8 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.7 · 72% consumer | NCT01601704: 38/4,455 (0.9%) on Bupropion; 16/4,450 (0.4%) control |
| Diarrhoea (diarrhea) | 3,638 | 1.2 1.2–1.2ROR 1.2 · χ² 135 / p 1e-31 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled adverse reaction exact term | serious PRR 1.4 | NCT01601704: 35/4,455 (0.8%) on Bupropion; 21/4,450 (0.5%) control |
| Vomiting | 3,432 | 1.6 1.5–1.6ROR 1.6 · χ² 717 / p 3e-158 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 1.8 | NCT01601704: 2/4,455 (0.0%) on Bupropion (serious AE) |
| Rash | 3,413 | 1.7 1.6–1.7ROR 1.7 · χ² 967 / p 1e-212 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 2.1 | NCT01601704: 10/4,455 (0.2%) on Bupropion; 3/4,450 (0.1%) control |
| Dyspnoea (shortness of breath) | 3,234 | 1.2 1.2–1.3ROR 1.2 · χ² 134 / p 3e-31 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled adverse reaction exact term | serious PRR 1.4 | NCT01601704: 1/4,455 (0.0%) on Bupropion; 1/4,450 (0.0%) control (serious AE) |
| Feeling abnormal | 3,164 | 2.8 2.7–2.9ROR 2.9 · χ² 3,748 / p <1e-300 | 2.8 EB05 2.7 · IC025 +1.4 3/3 methods agree | Labeled (related wording) related wording | serious PRR 3.2 · 75% consumer | NCT01601704: 7/4,455 (0.2%) on Bupropion |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Temperature regulation disorder — n=499, PRR 63.2
- Ejection fraction — n=103, PRR 45.6
- Sensitisation — n=121, PRR 40.0
- Retinitis — n=181, PRR 25.9
- Polycystic ovaries — n=139, PRR 20.7
- Food allergy — n=621, PRR 19.1
- Postictal state — n=82, PRR 18.3
- Joint destruction — n=121, PRR 17.8
- Lupus vulgaris — n=83, PRR 15.9
- Obstructive sleep apnoea syndrome — n=92, PRR 15.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Bupropion ↔ Seizures.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Bupropion?
In FDA FAERS, the most frequently co-reported reaction terms for Bupropion are nausea, fatigue, headache, depression, anxiety, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Bupropion have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) • Monitor for worsening and emergence of suicidal thoughts and behaviors.
Do FAERS signals prove that Bupropion causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8, effective 20210101; matched on
openfda.generic_name.exact:"BUPROPION" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 444 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,189 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
BUPROPION, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.